Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical …
X Liu, C Huang, PJ Bergen, J Li, J Zhang… - Journal of Zhejiang …, 2023 - Springer
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical …
X Liu, C Huang, PJ Bergen, J Li… - Journal of Zhejiang …, 2023 - pubmed.ncbi.nlm.nih.gov
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the infection and chemotherapy committee of the Shanghai medical …
X Liu, C Huang, PJ Bergen, J Li, J Zhang, Y Chen… - 2023 - cabidigitallibrary.org
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical …
X Liu, C Huang, PJ Bergen, J Li, J Zhang… - Journal of Zhejiang …, 2023 - europepmc.org
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical …
X LIU, C HUANG, PJ BERGEN, J LI… - Journal of Zhejiang …, 2023 - pesquisa.bvsalud.org
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
[HTML][HTML] Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai …
LIU Xiaofen, C HUANG, PJ BERGEN… - Journal of Zhejiang …, 2023 - ncbi.nlm.nih.gov
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
[引用][C] Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai …
X LIU, C HUANG, PJ BERGEN, J LI… - Journal of Zhejiang …, 2023 - europepmc.org
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical …
LIU Xiaofen, C HUANG, PJ BERGEN… - Journal of Zhejiang …, 2023 - pesquisa.bvsalud.org
Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …
bacterial infections, became available in China in Dec. 2017. As dose adjustments are …